<DOC>
	<DOCNO>NCT01892241</DOCNO>
	<brief_summary>Patients spontaneous decline HBV DNA non-randomly assign accept peginterferon alfa-2a entecavir therapy , n't accept antiviral regiment .</brief_summary>
	<brief_title>Efficacy Safety Peginterferon a-2a Patients Chronic Hepatitis B With Spontaneous Decline HBV DNA</brief_title>
	<detailed_description>It prospective , non-randomized , open-label study evaluate efficacy safety pegasys treatment chronic hepatitis B patient spontaneous HBVDNA decline acute exacerbation.Patients spontaneous decline HBV DNA ( decrease HBV DNA level 2 log ( 10 ) IU/mL compare baseline antiviral treatment ) acute exacerbation ( ALT 10-30ULN，TBIL 2-20mg/ml，PTA &gt; 60 % ) non-randomly divide 3 group : group A , B C. Before treatment , patient counsel advantage disadvantage take peginterferon nucleos ( ) ide analogue , subsequential treatment decide . Cases group A receive 180µg peginterferon alfa-2a ( Pegasys , Roche ) weekly 48 week . Group B C control group , case group B receive continual entecavir therapy ( 0.5 mg orally daily ) group C n't accept antiviral regiment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>This study focus subsequential antiviral therapeutic strategy chronic hepatitis B patient spontaneous decline HBV DNA acute exacerbation . Patients fullfilled follow criterias choose screening : They antiviral treatment naı¨ve positive hepatitis B surface antigen ( HBsAg ) least 6 month , positive HBeAg HBV DNA Level 500,000IU/ml . Their serum alanine aminotransferase level great 2 less equal 30 time upper limit normal range , peak value total bililubin range 2mg/ml 20mg/ml prothrombin time activity great 60 % . ALL patient hospitalize pretreated antiinflammation liver protection agent Stronger NeoMinophagen C , Polyunsaturated phosphatidylcholine ( Essentiale ) , Ursodeoxycholic Acid LGlutathione reduce , without nuclutide nucleoside . Their ALT、TBIL PTA monitor weekly HBVDNA level measure every two week . Patients eligible HBVDNA decline spontaneously 2 log ( 10 ) IU/mL ALT fall 10 ULN TBIL fall 2mg/ml within 8 week pretreatment . Patients advanced fibrosis , cirrhosis hepatoma exclude . Other cause chronic liver disease systematically check exclude coinfection HDV , HCV HIV , comorbidities alcoholism , autoimmune metabolic liver disease . Serious medical psychiatric illness usage corticosteroid immunosuppressive agent time study exclude . All patient study live Guangdong , province 100,000,000 population , demographic . Owing patient fear refusal liver biopsy , patient liver biopsy rest rely clinical method obtain equivalent information patient condition . In case , ultrasonorgraphy help filter patient advance fibrosis.The liver sonar examination perform two experienced hepatologists least three time patient .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Chronic hepatitis B , Spontaneous Decline HBV DNA , Peginterferon a-2a , entecavir</keyword>
</DOC>